Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03162783 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03162783: Completed Phase 2 study, sponsored by Aldeyra Therapeutics.
NCT03162783 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03162783, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Primary Outcome
Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Interventions
- DRUG ADX-102 Ophthalmic Solution (0.5%)
- DRUG ADX-102 Ophthalmic Solution (0.1%)
- DRUG ADX-102 Ophthalmic Lipid Solution (0.5%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 2 |
What the finished NCT03162783 record still lists
NCT03162783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which ADX-102 Ophthalmic Solution (0.5%) is the first listed.
NCT03162783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03162783 about?
NCT03162783 is a clinical study titled "A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome". The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
What is the current status of trial NCT03162783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-05-15. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT03162783?
The interventions under investigation include: ADX-102 Ophthalmic Solution (0.5%) (DRUG), ADX-102 Ophthalmic Solution (0.1%) (DRUG), ADX-102 Ophthalmic Lipid Solution (0.5%) (DRUG).
Who is sponsoring clinical trial NCT03162783?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03162783's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI